Edgewise Therapeutics, Inc. (EWTX) stock
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$41.37−0.67 (-1.59%)
Close on Nov 18, 2026Market cap $4.49BP/E –Yield –
Edgewise Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Edgewise Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$158.38M. For fiscal 2025 it was -$143.82M. The highest annual figure on record is -$14.63M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$143.82M | – |
| FY2024 | Dec 31, 2024 | -$109.03M | – |
| FY2023 | Dec 31, 2023 | -$91.95M | – |
| FY2022 | Dec 31, 2022 | -$52.64M | – |
| FY2021 | Dec 31, 2021 | -$33.51M | – |
| FY2020 | Dec 31, 2020 | -$14.63M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$32.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.23M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.86M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.27M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.74M | – |
See a number that looks wrong?